Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial

European Journal of Heart Failure

Volumn 9, Issue 2, 2007, Pages 110-112

  van Veldhuisen, Dirk J ^a   McMurray, John J V ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; STROKE;

ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33847785149     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.01.004     Document Type: Editorial

References (17)

1. Steinbrook R. Medicare and erythropoietin. N Engl J Med 356 (2007) 4-6
2. O'Meara E., Clayton T., McEntegart M.B., et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation 113 (2006) 986-994
3. Silverberg D.S., Wexler D., and Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4 (2002) 681-686 [review]
4. Abraham W., Klapholz M., Anand I., et al. Safety and efficacy of darbepoetin alfa treatment in anemic patients with symptomatic heart failure: a pooled analysis of two randomized, double-blind, placebo-controlled trials (abstract). Eur Heart J 27 (2006) 166-1667 [abstr suppl]
5. Young J.B., Anand I.S., Diaz R., et al. Reduction of events with darbepoetin alfa in Heart Failure (RED-HF) Trial (abstract). J Card Fail 12 suppl 1 (2006) S77
6. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
7. Drüeke T.B., Locatelli F., Clyne N., et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
8. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
9. Remuzzi G., and Ingelfinger J.R. Correction of anemia - payoffs and problems. N Engl J Med 355 (2006) 2144-2146 [Editorial]
10. Bolger A.P., Bartlett F.R., Penston H.S., et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 48 (2006) 1225-1227
11. Cleland J.G.F., Coletta A.P., Clark A.L., Velavan P., and Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure Meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 7 (2005) 937-939
12. Ghali J.K., Anand I., Abraham W.T., et al. Randomized, double-blind, placebo-controlled trial to assess the impact of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic heart failure: results from the Studies of Anemia in Heart Failure Trial (STAMINA-HeFT) (abstract). Eur Heart J 27 (2006) 166 [abstr suppl]
13. Van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing-regimens of darbepoetin-alfa on hemoglobin response and symptoms in patients with heart failure and anemia (abstract). J Am Coll Cardiol 47 Suppl A (2006) 61A
14. Mix T.C.H., Brenner R.M., Cooper M.E., et al. Rationale-Trial to Reduce cardiovascular events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149 (2005) 408-413
15. Tang Y.D., and Katz S.D. Anemia in chronic heart failure. Prevalence, etiology, clinical correlates, and treatment options. Circulation 113 (2006) 2454-2461
16. Van der Meer P., Voors A.A., Lipsic E., Van Gilst W.H., and Van Veldhuisen D.J. Erythropoietin in cardiovascular diseases. Eur Heart J 25 (2004) 285-291
17. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure; randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587